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In view of the fact that only a small part of the Mtb expressome has been explored for
identification of antigens capable of activating human T-cell responses, which is critically
required for the design of betterTB vaccination strategies, more emphasis should be placed
on innovative ways to discover new Mtb antigens and explore their function at the several
stages of infection. Better protective antigens forTB-vaccines are urgently needed, also in
view of the disappointing results of the MVA85 vaccine, which failed to induce additional
protection in BCG-vaccinated infants (1). Moreover, immune responses to relevant antigens
may be useful to identifyTB-specific biomarker signatures. Here, we describe the potency
of novel tools and strategies to reveal such Mtb antigens. Using proteins specific for differ-
ent Mtb infection phases, many new antigens of the latency-associated Mtb DosR-regulon
as well as resuscitation promoting factor proteins, associated with resuscitating TB, were
discovered that were recognized by CD4+ and CD8+ T-cells. Furthermore, by employing
MHC binding algorithms and bioinformatics combined with high-throughput human T-cell
screens and tetramers, HLA-class Ia restricted polyfunctional CD8+ T-cells were identified
in TB patients. Comparable methods, led to the identification of HLA-E-restricted Mtb epi-
topes recognized by CD8+ T-cells. A genome-wide unbiased antigen discovery approach
was applied to analyze the in vivo Mtb gene expression profiles in the lungs of mice, result-
ing in the identification of IVE-TB antigens, which are expressed during infection in the lung,
the main target organ of Mtb. IVE-TB antigens induce strong T-cell responses in long-term
latently Mtb infected individuals, and represent an interesting new group ofTB antigens for
vaccination. In summary, new tools have helped expand our view on the Mtb antigenome
involved in human cellular immunity and provided new candidates for TB vaccination.
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INTRODUCTION
M. TUBERCULOSIS ANTIGEN DISCOVERY: TRADITIONAL APPROACHES
Antigen discovery efforts have been a core component of mycobac-
terial research for over several decades, and have been markedly
facilitated since the availability of the Mycobacterium tuberculosis
(Mtb) genome sequence (2). A lot of different antigen discovery
approaches have been described, among which are biochemical-
, genetic-, expression library-, and peptide T-cell epitope-based
approaches. Using animal models, antigens with protective poten-
tial against Mtb infection have been discovered, some of which
have moved into human clinical trials (phase 1/2a) (3). Nev-
ertheless, T-cell epitopes have been identified in only 7% of all
predicted 4000 open reading frames (ORFs) of Mtb, and the top
30 most frequently studied protein antigens contain 65% of the
known epitopes (4). This leaves the Mtb “antigenome” incom-
pletely identified, which may be especially relevant in relation to
Mtb’s phase-dependent variation in gene expression (see below)
in response to varying environmental factors (5, 6).
Selection of vaccine candidates has been based largely on empir-
ical observations in the mouse, guinea pig, and non-human pri-
mate Mtb infection models and only a few antigens (mostly those
secreted during active replication of Mtb) have been exploited
as human vaccine candidates (7). Since Mtb alters its gene
expression profile significantly during intracellular stress inside
host macrophages, its antigen repertoire which is expressed and
exposed to the immune system varies considerably during dif-
ferent stages of infection under the pressure of various human
host defense mechanisms. A more profound understanding of
the actual Mtb antigenome expressed during different phases of
Mtb infection, particularly in the lung, the main target organ of
Mtb and the identification of the major T-cell epitopes involved,
is key to the design of better TB-vaccines and TB correlates of
immunity.
Almost all TB-vaccine antigen discovery approaches have
implicitly relied on the assumption that the Mtb antigens stud-
ied are expressed and presented by infected cells, where they are
supposedly recognized by T-cells that execute an appropriate effec-
tor response. The latter either assist phagocytes in controlling
or eliminating live bacteria through various intracellular path-
ways (phagosomal maturation and phagolysosomal fusion; oxida-
tive/nitrate intermediates; oxygen/nutrient deprivation; the activ-
ity of defensins and other anti-microbial peptides and enzymes;
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autophagy; apoptosis) (8), or – alternatively direct killing of
infected cells. Despite the significant advances made recently, rel-
atively little is known about the Mtb antigen repertoire, which
is truly expressed by the tubercle bacillus during its infection
cycle in human cells. Although abundantly expressed proteins
of Mtb are often the primary targets of research, less promi-
nently expressed antigens may have equally good or even supe-
rior vaccine potential. Better insight into the antigen repertoire
available for immune recognition on infected cells, its dynamic
changes as well as the quantitative relationship between the
various antigens expressed, should provide new directions for
antigen discovery and vaccine testing, with the potential to
complement or change current strategies used in TB-vaccine-
design.
CLASSICALMtb ANTIGEN DISCOVERY METHODS AND THE RISK OF
TUNNEL VISION
Indirect discovery approaches have mostly been the basis for
currently available evidence supporting the recognition of Mtb
antigens, including those on infected cells. Whereas the protective
potential of Mtb antigens is typically demonstrated using effective
vaccine platforms in animal models, the selection of the anti-
gens to be tested in such platforms is often biased and limited by
the antigen discovery procedures used. For example, as outlined
above, many studies have concentrated on antigens that are highly
expressed by bacteria under in vitro culture conditions in liquid
growth media. However, it is improbable that the same bacterial
transcriptomic or proteomic profiles expressed under optimal lab-
oratory growth conditions are the same as those expressed during
in vivo host infection.
A further important bias is that most Mtb antigens recognized
by human cells have been identified using IFN-γ assays as read
outs. As mentioned above, a considerable number of antigens
eliciting CD4+ IFN-γ Th1-cell responses has been identified (9),
but this represents almost certainly only a fraction of the poten-
tial Mtb “antigenome.” The number of IFN-γ-releasing antigen-
specific T-cells and the amount of total IFN-γ released have
remained widely used surrogate markers for the pro-inflammatory
immune response against Mtb. Thus, the antigens activating
other immune cells, including CD4+ T-cells that produce other
cytokines than IFN-γ such as Th2 cells, Tregs, Th17/22, cells
and cytolytic cells, as well as non-classically restricted (MHC-
Ib, see below) human T-cell subsets, remain largely incom-
plete or even unknown. However, the lack of (application of)
well-developed methods to identify Mtb-responsive T-cells other
than classical Th1 or proliferative responses have contributed
to this bias in Mtb antigens identified. Thus, it is vital to
develop better and more diverse assays that can be applied to
detect Mtb-induced responses across all relevant human T-cell
compartments.
SCOPE OF THIS REVIEW
Since our knowledge of the human Mtb antigenome is far from
complete as most currently known Mtb antigens were identified
using IFN-γ (Th1) production as read-out, and because there is
limited knowledge about the vaccine potential (protective efficacy)
of most antigens, we have followed several alternative strategies
to discover new Mtb antigens. Below, we will review the five
approaches we have pursued in recent years (Figure 1). It is likely
that many unexplored antigens for classical or non-classical T-cells
exist in the Mtb antigenome that may possess vaccine potential,
but appropriate tools and technologies are required to reveal these.
Improved and rational selection is needed to identify candidate
antigens with vaccine potential, based on comprehensive knowl-
edge of their patterns of expression, broad immunogenicity, suit-
ability for processing, HLA-binding and induction of protective
immunity in relevant model systems.
NEWMtb ANTIGEN DISCOVERY APPROACHES
INFECTION STAGE-SPECIFICMtb GENE EXPRESSION ANALYSES
Mtb DosR-regulon encoded proteins as latency antigens
As mentioned above, we have hypothesized that the design of
improved vaccination strategies requires a better understanding
of the Mtb proteins that are expressed during the different phases
of the Mtb intracellular life cycle, and their recognition by human
T-cell subsets.
During in vivo Mtb infection, environmental and host immune
factors induce bacterial dormancy, in the course of which Mtb
enters a state of non-or slowly replicating persistence, decreases
its metabolic activity and alters its gene expression pattern (5, 10).
This adjustment by the bacterium is thought to enhance its resis-
tance to environmental and host immune stress. Under in vitro
conditions that are considered to imitate part of the environment
encountered by tubercle bacilli in vivo in the immunocompetent
host (11) such as hypoxia, low dose nitric oxide, CO exposure
or in IFN-γ-activated macrophages, Mtb induces the expression
of the 48 gene encoding DosR (Rv3133c) regulon (12). In view
of this infection phase-specific upregulation, we first decided to
FIGURE 1 |Mtb antigen discovery approaches.
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study T-cell responses to these 48 DosR-regulon encoded anti-
gens (so-called TB latency antigens) in various ethnically and
geographically distinct cohorts in Europe (Italy, Germany, The
Netherlands) and Africa (The Gambia, Ethiopia, Uganda, and
South Africa) (13–19). In all cohorts we observed T-cell recog-
nition of Mtb DosR-regulon encoded latency antigens, partic-
ularly in TST+ individuals [designated latent TB (LTBI)] com-
pared to (ex-) TB patients. Thus, T-cell proliferation and IFN-γ
production to Mtb DosR-regulon encoded latency antigens are
characteristically seen in LTBI in diverse genetic and geographic
populations.
An unexpected but important finding was that Mtb DosR-
regulon encoded antigens were very poorly if at all recognized in
previously BCG-vaccinated individuals (20). Additionally, BCG-
vaccinated HLA-DR3 and HLA-A2 transgenic mice (21) failed
to respond to these antigens. The explanation for this lack of
induction of immune responses was not due to BCG’s ability to
express the DosR-regulon because transcriptional profiling of 14
different BCG strains, cultured under hypoxia, and nitric oxide
exposure in vitro, showed that genes of the DosR-regulon (except
Rv3133) were expressed to similar extents as observed in Mtb.
Moreover, comparison of the amino acid sequences of M. bovis
BCG and Mtb showed at least 97% homology with 85% of the
genes being completely identical (20). The explanation for this
phenomenon thus remains unknown, although it may relate to
an inability of BCG to enter a state of latency following intra-
dermal immunization. In agreement with the findings in human
LTBI, the Mtb DosR-regulon encoded latency antigens Rv1733c,
Rv2031c, and Rv2626c, were more prominently recognized in
chronic infected mice than in acute phase infection, whereas the
secreted protein Ag85B (Rv3804c) showed the opposite pheno-
type (18), again highlighting the preferential recognition of these
antigens in latent or long term as opposed to acute, early phase
infection.
An important group of individuals, the study of which shed
more light into this matter was composed of individuals who had
been Mtb infected for over 30 years ago, as witnessed by their
positive Mantoux skin tests, yet never developed disease despite
not having received any therapeutic treatment. Detailed immune
profiling experiments with cells from these long-term infected
individuals demonstrated strong Mtb DosR-regulon encoded
antigen-specific T-cell responses. Various epitopes were identified
that induced mono- and polyfunctional CD4+ and CD8+ T-cell
responses, in particular IFN-γ+TNF-α+ CD8+ effector memory-
or effector T-cells (22).
Considering the inability of BCG to induce immune responses
to latency antigens, TB vaccination strategies started to consider
incorporating DosR-regulon encoded antigens as a strategy to
complement and improve the current BCG vaccine. This was
demonstrated in TB mouse models using rBCG_ureC:hly express-
ing defined latency-associated antigens and test this construct for
long-term protection against an isolate of the Mtb Beijing/W
lineage (23). Expression of Rv2659c, Rv3407, and Rv1733c by
rBCG_ureC:hly showed long-term protection superior to BCG
in both lung and spleen compared to rBCG not expressing
latency antigens at day 200 post-infection after intradermal vac-
cination of mice. Even a latency antigen hsp16-derived peptide
linked to PAM2Cys adjuvant induced more efficient protection
than BCG (24).
Another type of latency antigens is represented by the so-
called “starvation” antigens, which are expressed under condi-
tions of nutrient deprivation. A hybrid protein consisting of two
secreted, acute phase-specific antigens, Ag85B and ESAT-6, fused
to the nutrient stress-induced antigen Rv2660c, was constructed.
In pre-exposure mouse models this hybrid protein formulated in
CAF01, promoted hybrid-specific T-cells, in particular polyfunc-
tional CD4+ T-cells and more efficient containment of late-stage
infection than the Ag85B-ESAT-6 vaccine and BCG (25). More-
over, in latent TB mouse models, post-exposure immunization
with this hybrid controlled TB reactivation and significantly low-
ered the number of bacteria in the lung compared to adjuvant
control mice.
Immunization of cynomolgus macaques with the multistage
Ag85B-ESAT-6-Rv2660c protein in IC31 adjuvant as a boost to
vaccination with BCG delayed and reduced clinical disease after
challenge with M. tuberculosis and also prevented reactivation of
latent infection (26). This boosting regimen resulted in efficient
control of M. tuberculosis infection and reduced rates of clinical
disease. Importantly, it improved survival of the NHP compared
to BCG alone and the vaccinated monkeys did not reactivate latent
infection after treatment with anti-TNF antibody.
Considering routine BCG vaccination practice in most TB
endemic countries, improved, rationally designed Mtb subunit
vaccines could be employed by simultaneous vaccination with
BCG, or booster vaccination on top of BCG, or by constructing
improved recombinant BCG strains expressing such antigens.
Resuscitation promoting factors as antigens
Although the factors that trigger bacterial reactivation and
resumption of intracellular growth remain largely known, Mtb
resuscitation promoting factors (Rpfs), which are secreted pro-
teins with high homology to the hormone-like protein secreted by
Micrococcus luteus (M. luteus) are believed to play an important
role in this respect (27, 28). The Mtb genome encodes five such
rpf genes [Rv0867c (rpfA), Rv1009 (rpfB), Rv1884c (rpfC), Rv2389c
(rpfD), and Rv2450c (rpfE)] that are able to stimulate the growth
of dormant mycobacteria and expression of the five Rpf proteins
is observed in vitro in actively replicating Mtb, in BCG as well as in
Mtb-infected human tissue (29–31). Addition of Rpf proteins to
sputa from TB patients improves the sensitivity of culture based
detection of live Mtb in certain conditions (32, 33). There is dif-
ferential rpf expression in cultures grown under hypoxia, nutrient
starvation, acidic conditions, stationary, non-cultivable, and resus-
citation phase-like conditions, suggesting that the role of Mtb Rpfs
may be infection stage dependent but likely is not identical for all
Rpfs (34).
In view of the role of Mtb Rpf proteins in the resuscitation
of mycobacteria, immunity against these proteins may reflect the
ability to detect the presence of actively replicating Mtb organ-
isms at an early stage. Thus, immunity against Rpf proteins
may play a role in host control bacterial reactivation. In line
with the immunogenicity found in mice for Rv0867c, Rv1009,
Rv2389c, and Rv2450c (35), we identified the first human Mtb
Rpf-specific T-cell responses against Mtb Rpfs (19), showing
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IFN-γ production in TST+ individuals in response to Rv1009,
Rv1884c, and Rv2450c and to a lesser extent Rv0867c, whereas
hardly any IFN-γ was detected in individuals without a posi-
tive Mantoux. More detailed analyses of the immune responses
to Mtb Rpf proteins in Mtb-exposed individuals, including long-
term LTBI non-progressors showed frequent and significant T-cell
responses against both Rv0867c and Rv2389c and identified novel
Mtb Rpf epitopes, including a single highly dominant peptide
epitope in Rv2389c. Of note, Mtb Rpf-specific polyfunctional
memory CD4+ and particularly CD8+ T-cell memory responses
were observed in response to Rv0867c and Rv2389c Rpf proteins.
The polyfunctional phenotype of these cells was both single and
double cytokine producing CD4+ and CD8+ T-cells, support-
ing the concept that CD8+ T-cells may be important in long-
term control of Mtb infection. Based on these collective studies,
we envisage that a combination of multiple phase-specific anti-
gens may significantly improve the protective potential of new
TB-vaccines (25, 36). Thus, subunit vaccines based on a combi-
nation of latency and Rpf antigens could be designed that induce
responses able to eliminate Mtb bacilli in their dormant state, as
well as inhibit Mtb bacilli that are trying to recommence active
replication.
UNBIASEDMtb “GENOMEWIDE” ANTIGEN DISCOVERY APPROACHES
HLA-class Ia presented human CD8+ T-cell epitopes
Despite the fact that CD4+ T-cells play a vital role in immu-
nity against Mtb, it is becoming evident that also CD8+ T-cells
contribute to host defense against Mtb by virtue of their ability
to produce pro-inflammatory cytokines (9, 37, 38), lyse infected
host cells (39), and kill mycobacteria (40). Despite the fact that
the antigens and epitopes activating human Mtb-specific CD8+
T-cell responses have been less well defined than those for CD4+
T-cells, some groups have been able to isolate such CD8+ T-
cells from humans (41–44). Unexpectedly, it was reported that
ex vivo frequencies of CD8+ T-cells recognizing epitopes from
six different Mtb proteins in patients with active TB were lower
as evaluated by specific tetramers, but normalized following ther-
apy to frequencies comparable to subjects with LTBI. Additionally,
CD8+ T-cells with an IL-2+/IFN-γ+ phenotype were particu-
larly reduced or found absent in active TB patients (45). Nev-
ertheless, it has remained challenging to identify the role and
function of CD8+ T-cells in TB, urging for new strategies and
appropriate tools to decipher their specificities. Using classic
approaches it would not be feasible to screen the approximately
1 million possible 9-mers in the Mtb proteome for CD8+ T-cell
responses.
A recently described approach addressed this issue exploiting
an integrated computational and proteomic approach to screen
10% of the Mtb proteome for antigens that are recognized by
CD8+ T-cells: using a synthetic Mtb peptide library consisting
of 15-mers (11 aa overlap) with high probability of containing
CD8+ T-cell epitopes, IFN-γ release by Mtb-specific, HLA-class
I-restricted CD8+ T-cell clones was measured by ELISPOT assay
(46). This study identified the EsxJ family, PE9, and PE_PGRS42 as
three novel CD8 antigens and validated the use of peptide library-
based approaches a new tool for identification of Mtb epitopes
recognized by CD8+ T-cells.
An alternative method of combined bioinformatics- and func-
tional immunological screening strategies, called “reverse antigen
discovery,” was applied by our group to identify HLA-class Ia
restricted, CD8+ T-cell antigens. Through peptide-binding pre-
diction algorithms, potential peptide epitopes of Mtb antigens
were identified restricted by three major HLA-class Ia supertypes
(HLA-A2, -A3, and -B7) which together cover more than 80%
of the population from different ethnic groups (47). Over 400
synthetic Mtb peptides with predicted binding affinities for HLA-
A*0201, HLA-A*0301, and HLA-B*0702 (representing the above
supertypes) were tested for HLA-binding and induction of prolif-
eration of CD8+ T-cells. This study led to the identification of>60
new Mtb epitopes. Further validation of the most interesting epi-
topes was executed using HLA-class I-tetramers and assessment of
peptide-induced intracellular cytokine staining to measure multi-
functional CD8+ T-cell responses in cured TB patients and healthy
control individuals. In depth analysis of 18 prominently recog-
nized HLA-A*0201-binding, Mtb peptides using CD8+ T-cells
of cured TB patients, showed IFN-γ, IL-2, and TNF-α, mono-,
dual-, and triple-positive CD8+ T-cells. Interestingly, in Mtb-
non-infected individuals these polyfunctional CD8+ T-cells were
absent, which argues for their priming during in vivo Mtb infec-
tion. Thus, this study is consistent with the notion that there is a
much broader repertoire of CD8+ T-cells, which can be identified
with specific bioinformatic approaches combined with functional
immune assays.
An additional alternative strategy, not yet applied in the identi-
fication of new Mtb antigens, could be the use of HLA-conditional
ligands for high-throughput tetramer generation (48). This tech-
nique allows production of HLA ligands that form stable com-
plexes with HLA molecules but can be cleaved upon UV irra-
diation. The resulting empty, peptide-receptive HLA molecules
can be loaded under native conditions with selected epitopes in
a high-throughput and HLA-epitope tetramers can be generated
and subsequently used for T-cell detection.
Summarized innovative detection methods for CD8+ T-cells
can and will allow identification of protective- and pathogenic
immunity, which can be used to monitor vaccine- and treatment
efficacy.
HLA-class II presented+ human T-cell epitopes
A similar genome-wide approach was recently followed by Sette
et al. to identify CD4+ T-cell epitopes: the Mtb genome was mined
for potential peptide epitopes presented by HLA-class II mole-
cules to CD4+ T-cells (49). The approach relied on predictions
of HLA-binding capacity for a panel of DR, DP, and DQ alleles
representative of those most commonly expressed in the general
population, coupled with high-throughput ELISPOT assays. They
found that secreted antigens as well as proteins involved in the
active secretion process were dominant targets of the CD4+ T-cell
response in the latently infected individuals tested in San Diego
who successfully contain Mtb infection.
Responses were highly focused on three broadly immunodomi-
nant antigenic islands, all related to bacterial secretion systems and
composed by several distinct ORFs. These data suggest that vac-
cination with one or few defined antigens will fail to replicate the
response associated with natural immunity. Importantly, they also
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found that the CD4+ T-cells responding were largely restricted
to the CXCR3+CCR6+ memory subset. The identification of this
immunodominant population of memory T-cells characterized
suggests that the response is shaped uniquely by Mtb-associated
factors.
In analogy to the above results for CD8+ T-cells, these results
again underline the power of an unbiased, genome-wide, Mtb
antigen discovery approaches.
HLA-class Ib presented CD8+ human T-cell epitopes
The identification of Mtb antigens for human CD8+ T-cells
focus has been focused almost entirely on classical HLA-class
Ia and to a lesser extent, on CD1 a, b, c restricted CD8+ T-cell
responses (50). In this respect, the polymorphism of the classi-
cal HLA-class Ia molecules (HLA-A, -B, -C) which include more
than 500, 850, or 270 unique alleles, respectively, is an impor-
tant factor to be considered for vaccine development due to the
considerable variations in peptides that can bind to each HLA-
class Ia molecule. In contrast, the HLA-class Ib genes HLA-E, -F,
and -G exhibit restricted polymorphism with only 3, 4, and 10
alleles, respectively (51). This might argue for distinct roles for
MHC-class Ia and class Ib molecules in host defense to infectious
diseases. Non-classical HLA-class I molecules can present anti-
gens of both self and foreign (microbial) origin to CD8+ T-cells
(52–54). The fact that their allelic variation is limited provides
an opportunity for vaccine-design. Since the two most impor-
tant variants of HLA-E, HLA-ER (E*0101), and HLA-EG (E*0103),
occur in equal frequencies amongst different populations (55) and
can present antigens derived from pathogens including Mtb, Mtb
antigen(s) recognized by HLA-E restricted CD8+ T-cell clones
represent interesting targets for vaccine development. Moreover,
HLA-E is not downregulated by HIV in contrast to HLA-A and
-B offering possibilities for vaccination of HIV-infected individ-
uals as well (56). However, the nature of the epitopes recog-
nized by HLA-E restricted CD8+ T-cells remained unknown until
recently (57).
Although HLA-E molecules can clearly interact with CD94
molecular complexes expressed predominantly by NK cells,HLA-E
is also known to trigger microbial-specific cytotoxic CD8+ T-cells
(58, 59). In mice, CD8+ T-cells restricted by the murine HLA-E
equivalent, Qa-1 were found to have the ability to induce immune-
suppression (60), revealing yet another function of non-classically
restricted CD8+ T-cells.
To identify HLA-E-restricted Mtb antigens which could be
exploited for TB vaccination, we applied bioinformatics, HLA-E
peptide-binding assays, and immunological screening, in anal-
ogy to the approach used for identification of classical MHC-Ia
restricted CD8 T-cell epitopes (61). With this method we iden-
tified 69 Mtb peptides, derived from a large variety of Mtb
antigens, which were presented by HLA-E molecules to human
CD8+ T-cells. We could demonstrate that CD8+ T-cells from both
mycobacterium responsive adults and BCG-vaccinated infants,
but not negative controls, proliferated in response to the identi-
fied Mtb peptides. These CD8+ T-cells displayed cytotoxic activity
against target-cells expressing HLA-E loaded with specific pep-
tides, in the absence of any class Ia molecules, and were able to
lyse M. bovis BCG infected human macrophages demonstrating
that HLA-E restricted antigens are naturally processed during
infection. Besides, several HLA-E-restricted, Mtb-specific CD8+
T-cells were able to suppress proliferation of bystander CD4+
T-cells. This suppression depended on cell–cell contact and was
mediated, at least in part, by membrane bound TGFβ1. These
data underscore that human CD8+ T-cells are highly multifunc-
tional, and can combine diverse functions such as suppressive and
cytotoxic functions. If BCG vaccination would be able to prime
HLA-E restricted T-cell responses, HLA-E peptide-based vaccines
might be able to boost such BCG-primed responses. The dual
character of the response induced in the context of HLA-E may
lead to induction of protection as well as balanced regulation of
inflammation, which, might be exploited to limit inflammatory
pathology in TB.
In vivo expressed Mtb (IVE-TB) antigen-derived human T-cell
epitopes
Since the lung represents the principal organ where TB disease
is manifested, vaccine-induced immune responses need to target
Mtb during pulmonary infection. In this respect, it is important
to note the significant impact of the alteration of Mtb’s gene
expression profile during intracellular stress inside host alveolar
macrophages, on the Mtb antigen repertoire that is presented to
the immune system. Thus, we hypothesized that a more profound
understanding of the real time Mtb “antigenome” expressed dur-
ing infection in the lung and its recognition by the human immune
system, including non-classical T- and B-cells, is vital to develop
better vaccination strategies. To identify novel antigens with vac-
cine potential, we used an unbiased genome-wide approach based
on comprehensive gene expression data from Mtb during infec-
tion of four genetically related but distinct mouse strains (62).
These strains represent key features of human TB with a spec-
trum of TB susceptibility, including the development of necrotic
lesions and granuloma formation, which are regulated by the
super-susceptibility to tuberculosis 1 (sst1) locus as well as modi-
fier background genes (62). We investigated the in vivo expression
of 2170 Mtb genes, most of which represent the first gene of each
predicted Mtb operon, during infection in the lungs. To select can-
didate antigens, stringent selection approaches were then applied
to identify a list of in vivo expressed Mtb (designated IVE-TB)
genes. The resulting 16 most consistently expressed Mtb genes were
produced as recombinant proteins and their immunogenicity was
analyzed in PBMC of TST+ healthy, TB affected individuals, TB
patients as well as long-term LTBI. Seven of the identified IVE-TB
antigens were strongly immunogenic in TST+, ESAT-6/CFP10-
responsive individuals, but not in E/C negative TST+ individuals
and healthy mycobacterial naïve individuals, indicating that these
antigens are presented during natural Mtb infection. Importantly,
IVE-TB antigen-specific responses could be detected in long-term
LTBI, who had been exposed to Mtb many years ago yet never
developed TB symptoms despite not having had preventive treat-
ment. The most pronounced T-cell subsets recognizing IVE-TB
antigens were identified as IFN-γ+/TNF-α+ CD8+ T-cells and
TNF-α+/IL-2+ CD154+CD4+ T-cells of which the former were
major contributors to IFN-γ production. Since IFN-γ+/TNF-α+
CD8+ T-cells were also the most prominent subset in the response
to Rpf and DosR proteins, this suggests that the development of
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specific differential T-cell subsets may be unrelated to the nature
of the specific protein antigen involved.
Thus, the analysis of in vivo expression patterns during pul-
monary Mtb infection to identify IVE-TB antigens, combined with
detailed immune profiling in humans, led to the identification of
IVE-TB as a new class of TB antigens, with the potential for TB
vaccination. Our most recent results indeed reveal their protec-
tive efficacy in various animal models (63). Importantly, IVE-TB
antigen discovery strategies can be applied also to other infec-
tious diseases caused by complex pathogens and represent a novel
approach for antigen discovery in general.
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